Informative gene network for chemotherapy-induced peripheral neuropathy

BackgroundHost genetic variability has been implicated in chemotherapy-induced peripheral neuropathy (CIPN). A dose-limiting toxicity for chemotherapy agents, CIPN is also a debilitating condition that may progress to chronic neuropathic pain. We utilized a bioinformatics approach, which captures the complexity of intracellular and intercellular interactions, to identify genes for CIPN.MethodsUsing genes pooled from the literature as a starting point, we used Ingenuity Pathway Analysis (IPA) to generate gene networks for CIPN.ResultsWe performed IPA core analysis for genes associated with platinum-, taxane- and platinum-taxane–induced neuropathy. We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum–induced neuropathy.ConclusionNeurotoxicity is common in cancer patients treated with platinum compounds and anti-microtubule agents and CIPN is one of the debilitating sequela. The bioinformatic approach helped identify genes associated with CIPN in cancer patients.

[1]  M. Spitz,et al.  Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. , 2013, Journal of pain and symptom management.

[2]  Jun Liang,et al.  Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer , 2010, Journal of Korean medical science.

[3]  G. Bennett,et al.  Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy , 2004, Pain.

[4]  G. Abrams,et al.  Associations Between Cytokine Genes and a Symptom Cluster of Pain, Fatigue, Sleep Disturbance, and Depression in Patients Prior to Breast Cancer Surgery , 2015, Biological research for nursing.

[5]  G. Bennett,et al.  Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. , 2008, Pain medicine.

[6]  W. Vach,et al.  GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients , 2013, Acta oncologica.

[7]  Seung-Yong Jeong,et al.  Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer , 2013, Cancer Chemotherapy and Pharmacology.

[8]  K. Stankovic,et al.  Metabolomic and Network Analysis of Pharmacotherapies for Sensorineural Hearing Loss , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[9]  L. Radbruch,et al.  Assessment and treatment of neuropathic cancer pain following WHO guidelines , 1999, Pain.

[10]  P. Albertsson,et al.  The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. , 2010, Oncology letters.

[11]  A. Argyriou,et al.  Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy? , 2010, European journal of neurology.

[12]  Yen-Chung Chen,et al.  Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX‐4 treatment in Asian patients with colorectal carcinoma , 2010, Cancer science.

[13]  R. Lothe,et al.  Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study , 2007, Journal of Translational Medicine.

[14]  E. Ong Controlled-Release Oxycodone in the Treatment of Neuropathic Pain of Nonmalignant and Malignant Causes , 2008, Oncology.

[15]  A. Khrunin,et al.  Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients , 2010, The Pharmacogenomics Journal.

[16]  M. Baiget,et al.  Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy , 2009, British Journal of Cancer.

[17]  G. Ehninger,et al.  The T_T genotype within the NME1 promoter single nucleotide polymorphism −835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia , 2012, Leukemia & lymphoma.

[18]  R. Milne,et al.  Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.

[19]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[20]  F. Carvalho,et al.  Interleukin-1β genotype and circulating levels in cancer patients: metastatic status and pain perception. , 2014, Clinical biochemistry.

[21]  P. Novotny,et al.  Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. , 2003, The journal of supportive oncology.

[22]  E. Gamelin,et al.  Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway , 2007, Clinical Cancer Research.

[23]  H. Thaler,et al.  Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms , 1994, Neurology.

[24]  C. Reyes-Gibby,et al.  Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Caldas,et al.  Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.

[26]  M. Stillman,et al.  Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.

[27]  L. Carey,et al.  CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  E. Bruera,et al.  Molecular epidemiology, cancer-related symptoms, and cytokines pathway. , 2008, The Lancet. Oncology.

[29]  K. Kumamoto,et al.  Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients , 2013, Oncology letters.

[30]  K. Kitagawa,et al.  Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. , 2010, International journal of clinical pharmacology and therapeutics.

[31]  K. Stankovic,et al.  A Comprehensive Network and Pathway Analysis of Human Deafness Genes , 2013, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[32]  W. Vach,et al.  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.

[33]  Yusuke Nakamura,et al.  A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 , 2012, Clinical Cancer Research.

[34]  Y. Ling,et al.  Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy. , 2013, Molecular medicine reports.

[35]  F. Matsuda,et al.  Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. , 2010, Cancer epidemiology.

[36]  A. Caraceni,et al.  An international survey of cancer pain characteristics and syndromes , 1999, PAIN.

[37]  A. González-Neira,et al.  Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy , 2013, Journal of Medical Genetics.

[38]  J. Lundeberg,et al.  Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. , 2012, Gene.

[39]  B. Schmidt,et al.  Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. , 2012, The journal of pain : official journal of the American Pain Society.

[40]  R. Albert,et al.  The large-scale organization of metabolic networks , 2000, Nature.

[41]  H. Chung,et al.  Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. , 2009, Gynecologic oncology.

[42]  Junshik Hong,et al.  Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis , 2011, Cancer Chemotherapy and Pharmacology.

[43]  H. Eom,et al.  Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. , 2010, Cancer genetics and cytogenetics.

[44]  G. Y. Wong,et al.  Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy , 2007, Cancer.

[45]  S. Steinberg,et al.  ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel , 2008, Clinical Cancer Research.

[46]  A. Gibson The European Society for Medical Oncology (ESMO) , 2019, Annals of Oncology.

[47]  E. Bruera,et al.  The Influence of Tumor Necrosis Factor-α −308 G/A and IL-6 −174 G/C on Pain and Analgesia Response in Lung Cancer Patients Receiving Supportive Care , 2008, Cancer Epidemiology Biomarkers & Prevention.

[48]  H. Goldschmidt,et al.  Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Spitz,et al.  Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes , 2013, Supportive Care in Cancer.

[50]  W. Vach,et al.  Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. , 2012, Basic & clinical pharmacology & toxicology.

[51]  H. Goldschmidt,et al.  Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. , 2010, The Lancet. Oncology.

[52]  L. Carey,et al.  CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel , 2012, Breast Cancer Research and Treatment.

[53]  Jennie Malboeuf Algorithm , 1994, Neurology.

[54]  A. Argyriou,et al.  Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy , 2009, Oncology.

[55]  T. Rebbeck,et al.  CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia , 2003, British journal of haematology.

[56]  M. Indelli,et al.  Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients , 2010, Breast Cancer Research and Treatment.

[57]  N. Cherny Opioid analgesics: comparative features and prescribing guidelines. , 1996, Drugs.

[58]  C. Punt,et al.  Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. , 2009, European journal of cancer.

[59]  P. Zis,et al.  Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. , 2008, Pain medicine.

[60]  H. Goldschmidt,et al.  Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients , 2011, Haematologica.

[61]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Maier,et al.  Immune regulation of central nervous system functions: from sickness responses to pathological pain , 2005, Journal of internal medicine.

[63]  M. Dolan,et al.  Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy , 2012, Clinical Cancer Research.

[64]  A. Dickenson,et al.  Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy , 2003, Brain Research.

[65]  P. Tonali,et al.  Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity , 2011, Cancer Chemotherapy and Pharmacology.

[66]  M. Loriot,et al.  Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  G. Mulligan,et al.  Genetic variation associated with bortezomib-induced peripheral neuropathy , 2011, Pharmacogenetics and genomics.

[68]  A. Khrunin,et al.  Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. , 2014, Pharmacogenomics.

[69]  C. Bokemeyer,et al.  Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  G. Hortobagyi,et al.  Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221) , 2011, Breast Cancer Research and Treatment.

[71]  M. Loriot,et al.  Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy , 2006, Clinical Cancer Research.

[72]  E. Bruera,et al.  Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. , 2009, Journal of pain and symptom management.

[73]  O. Mir,et al.  Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  Robert Brown,et al.  Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  J. Stinson,et al.  Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. , 2007, Pain research & management.

[76]  C. Loprinzi,et al.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. , 2008, European journal of cancer.

[77]  Hyo-jin Kim,et al.  Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. , 2009, Oncology reports.

[78]  T. Nurmikko,et al.  EFNS guidelines on pharmacological treatment of neuropathic pain , 2006, European journal of neurology.

[79]  D. Sargent,et al.  Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. , 2010, Journal of Clinical Oncology.

[80]  S. Steinberg,et al.  Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. , 2006, European journal of cancer.

[81]  Raya Khanin,et al.  How Scale-Free Are Biological Networks , 2006, J. Comput. Biol..

[82]  A. Navarro,et al.  Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. , 2011, Leukemia research.

[83]  E. Wiemer,et al.  CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity , 2013, Clinical Cancer Research.

[84]  David Schiff,et al.  Neurologic complications of chemotherapy agents , 2007, Current opinion in neurology.

[85]  L. Carey,et al.  Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy , 2014, Breast Cancer Research and Treatment.

[86]  M. Taron,et al.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  M. Clark,et al.  SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. , 2012, Lung cancer.

[88]  G. Bennett,et al.  Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells , 2008, Experimental Neurology.

[89]  P. Vivas-Mejia,et al.  MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models , 2008, British journal of pharmacology.

[90]  K. Nathanson,et al.  Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF) , 2012, Front. Endocrin..

[91]  J. Aparicio,et al.  Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  Harald Breivik,et al.  International Association for the Study of Pain: update on WHO-IASP activities. , 2002, Journal of pain and symptom management.

[93]  P. Söderkvist,et al.  Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. , 2009, Basic & clinical pharmacology & toxicology.

[94]  Robert Brown,et al.  Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity , 2013, Clinical Cancer Research.

[95]  F. Innocenti,et al.  A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen , 2012, The Pharmacogenomics Journal.

[96]  M. Friedlander,et al.  Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. , 2008, Current medicinal chemistry.

[97]  S. Maier,et al.  Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.

[98]  M. Relling,et al.  Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  B. Schmidt,et al.  Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery. , 2014, The journal of pain : official journal of the American Pain Society.

[100]  Joon-Oh Park,et al.  Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients , 2012, Cancer.

[101]  J. Ahn,et al.  Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. , 2014, European journal of cancer.

[102]  Y. Bang,et al.  Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker , 2008, BMC Cancer.

[103]  Cristina Santos,et al.  Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study , 2013, Cancer.